Rare diseases
Investigational molecules
Locations
Back to Germany1 444 clinical trials in Hochheim Am Main, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in GermanyKlinischeStudien.de(opens in a new tab)Study on the Effects of Upadacitinib in Adults and Adolescents with Non-Segmental Vitiligo Eligible for Systemic Treatment
GermanyStudy on the Effects of Astegolimab and Drug Combination for Patients with Chronic Obstructive Pulmonary Disease (COPD)
GermanyStudy on the Effectiveness of Povorcitinib for Adults with Nonsegmental Vitiligo
GermanyStudy on Long-Term Safety and Efficacy of Deucravacitinib for Patients with Moderate-to-Severe Plaque Psoriasis
GermanyStudy of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke
GermanyStudy on Rezpegaldesleukin for Treating Moderate-to-Severe Atopic Dermatitis in Adults
GermanyStudy on Long-Term Safety of Cendakimab for Adults and Adolescents with Eosinophilic Esophagitis
GermanyStudy of Baricitinib for Children and Adolescents with Moderate-to-Severe Atopic Dermatitis
GermanyStudy of resmetirom (MGL-3196) in patients with Non-Alcoholic Steatohepatitis (NASH) to prevent liver damage and disease progression
GermanyStudy on the Effects of AR1001 (Mirodenafil Dihydrochloride) for Patients with Early Alzheimer's Disease
GermanyStudy on the Long-Term Safety and Efficacy of Oral Ozanimod for Patients with Moderate to Severe Crohn's Disease
GermanyStudy on the Effects of Semaglutide in Patients with Non-Alcoholic Steatohepatitis (NASH) and Fibrosis Stages 2 or 3
GermanyThe busiest research cities in the country
What the registry says about research in the country
Innovative research focusing on Gaucher disease and Niemann-Pick disease, exploring new therapeutic approaches for these challenging genetic conditions. Studies aim to evaluate novel treatments for improving neurological symptoms and overall patient outcomes.
Clinical investigations evaluating venglustat and nizubaglustat's effectiveness in managing disease progression.
Research centered on treating Mucopolysaccharidosis Type II (Hunter Syndrome) and Pompe disease, with multiple studies investigating innovative enzyme replacement therapies and novel drug combinations.
Evaluation of treatments like JR-141 and cipaglucosidase alfa for improved patient outcomes.
Studies focused on preventing respiratory syncytial virus infections in older adults, with particular attention to vaccine development and immune response assessment.
Investigation of revaccination strategies and long-term protection against respiratory infections.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
